



January 30, 2023

Kidswell Bio Corporation

Code: 4584 (TSE Mothers)

Masaharu Tani, President & CEO

Update of clinical research plan of Nagoya University

Tokyo, January 30, 2023 – Related to a patent application on cell therapy for cerebral palsy utilizing SHED (stem cells from human exfoliated deciduous teeth) with Nagoya University in October, 2022, Certified Regenerative Medicine Committee of Nagoya University has discussed the clinical research plan "clinical trial to examine the safety and tolerability of a single administration of autologous SHED for children with cerebral palsy," which was laid out under the initiative of Nagoya University.

About Kidswell Bio Corporation (KWB)

Kidswell Bio Corporation will challenge pediatric disease as a new field, in addition to intractable and rare diseases on which KWB has also been focusing for R&D. We would like to contribute to children who have hopes and dreams for their bright future. Furthermore, with our biotech expertise and children's potential vital force such as SHED, stem cell from exfoliated deciduous teeth, we envision creating new pharmaceuticals and therapeutics for all people under "Kids Well, All Well."

Contact:

Kidswell Bio Corporation

Tel: +81-3-6222-9547 Mail: info@kidswellbio.com